Ctgf clinical trial
WebFeb 2, 2014 · Clinically, CTGF expression correlates with melanoma progression and metastasis. Inhibition of CTGF, either genetically or with a specific anti-CTGF … WebMay 25, 2024 · Introduction. Connective tissue growth factor (CTGF, CCN2), a cysteine-rich matricellular protein, is an important profibrotic mediator in several fibrotic disorders, including idiopathic pulmonary fibrosis (IPF) (1, 2).In IPF, promising results of the PRAISE trial were recently published, which was a phase II randomized trial of Pamrevlumab …
Ctgf clinical trial
Did you know?
WebJun 6, 2012 · CTGF is a secreted matricellular protein with very complex biology. It has been shown to modulate many signaling pathways leading to cell adhesion and migration, … WebConnective-tissue growth factor (CTGF), also known variously as CCN2 (Cyr61 [cysteine-rich protein 61] and NOV [nephroblastoma overexpressed gene], ... Results of a randomized, double-blind, placebo-controlled phase 2 clinical trial testing pamrevlumab in IPF patients, PRAISE (prospective randomized amlodipine survival evaluation), ...
WebAug 6, 2024 · The efficacy of CTGF inhibition previously observed in a wide variety of animal models is now being evaluated in clinical trials. Therefore, CTGF appears to be a candidate therapeutic target for kidney disease. In this review, we present the current knowledge of the involvement of CTGF in kidney disease, especially glomerulonephritis. WebSeveral clinical trials are now ongoing that investigate the therapeutic value of targeting CTGF in fibrosis, diabetic nephropathy, and pancreatic cancer. [5] CTGF (CCN2) has …
WebCTGF is critically involved in processes of progressive fibrosis, including DKD. This phase 1, open-label, dose-escalation trial evaluated safety, pharmacokinetics, and possible therapeutic effects of FG-3019 on albuminuria, proteinuria, and tubular proteins. WebOct 29, 2024 · CTGF (6q23.2) is a relatively short gene and consists of 5 exons that code for a 349-amino acid protein, the first exon codes for a signal peptide (for secretion) and …
WebOct 14, 2014 · Connective tissue growth factor is a new ligand of epidermal growth factor receptor. J. Mol. Cell Biol. 5, 323–335 (2013). CAS PubMed Google Scholar Cheng, X. et …
WebApr 3, 2024 · The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. ... including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s ... bsdr therapyWebDec 15, 2008 · FibroGen, Inc. today announced that an open-label, phase 1 clinical trial designed to evaluate the safety and tolerability of FG-3019, a fully human monoclonal antibody against connective tissue growth factor (CTGF), in combination with gemcitabine and erlotinib in patients with locally advanced or metastatic pancreatic … bsdschedule4qcy21.pdf marines.milWebSep 9, 2024 · Connective tissue growth factor (CTGF) is a polypeptide that has been shown to be overexpressed in various fibrotic disorders, suggesting its involvement in … excel value present in another columnWebFeb 25, 2024 · FG-3019 (pamrevlumab) is a human monoclonal antibody (mAb) against CTGF that has shown efficacy in a randomized, placebo-controlled phase 2 clinical trial in subjects with idiopathic pulmonary fibrosis , as well as in phase 2 clinical trials for treatment of pancreatic cancer and Duchenne muscular dystrophy (NCT02210559 and … excelvan projector no lightWebJan 8, 2024 · NIS793 is a monoclonal antibody blocking TGFβ1 and TGFβ2 and is being tested in combination with the anti-PD1 antibody PDR001 in a phase 1 clinical trial of patients with advanced malignancies ... excel value of row search isnumberWebCCN (for CYR61/ CTGF /NOV) proteins were identified originally from diverse cellular contexts and studied for their growth-promoting activities. It is now known that there are … bsd s4 malWebCTGF, also known as CCN2 or connective tissue growth factor, is a ... Several clinical trials are now ongoing that investigate the therapeutic value of targeting CTGF in fibrosis, diabetic nephropathy, and pancreatic cancer. CTGF (CCN2) has recently been implicated in mood disorders, ... excelvan lighting